1034.5000 -2.40 (-0.23%)
NSE Sep 16, 2025 15:31 PM
Volume: 511.7K
 

logo
Zydus Lifesciences Ltd.
16 Nov 2017, 12:00AM
1034.50
-0.23%
ICICI Securities Limited
EBITDA margins improved 503 bps to 26.5% (I-direct estimate: 26.0%), mainly due to gLialda launch under exclusivity. EBITDA increased 66% YoY to | 857 crore (I-direct estimate: | 799 crore) PAT increased 32% YoY to | 503 crore (I-direct estimate: | 609 crore) due to the strong operational performance, which was partly offset by higher tax rate (29.8% vs | 14.8% in Q2FY17) US momentum improves with Moraiya EIR, expansion of other facilities The US (41% of revenues) has grown at a CAGR of 25% in FY13-17...
Zydus Lifesciences Ltd. is trading above all available SMAs
More from Zydus Lifesciences Ltd.
Recommended